BD SurePath™ Pap Test


BD SurePath™ liquid-based Pap test

BD SurePath™ liquid-based Pap test

The BD SurePath™ liquid-based Pap test is an FDA approved thin-layer cell preparation process intended for use in the screening and detection of cervical cancer, pre-cancerous lesions, atypical cells and all other cytologic categories as defined by The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses.1

FOCUS: Cervical Disease Detection!

BD SurePath™ liquid-based Pap test:

  • 64.4% increase in HSIL+ lesions detection2 in comparison to the conventional Pap smear.
  • Significantly reduces Unsatisfactory and Satisfactory But Limited By (SBLB) cases3 for potentially fewer patient call-backs.
  • Allows physician to perform Pap tests in a wide variety of clinical presentations (e.g. blood, mucous and inflammation) with maximum confidence in the result due to the proprietary BD SurePath™ Cell Enrichment process used in the lab.

BD SurePath™ Pap test has a unique, easy to use collection process that standardizes the collection process and ensures 100% of the collected sample is sent to the laboratory for processing. No diagnostic cells are discarded in the clinic, as is true with “rinse and swish” systems, which on average can result in the loss of on average, 37% of the collected sample during cell transfer4.

BD SurePath™ Sample Collection:

Step 1: Collect


Collect the cytology sample using either a broom-like device or combination brush/spatula with detachable heads.
 
BD SurePath™ Collection process or BD SurePath™ Collection process
 
Step 2: Drop

Drop the detachable head into the BD SurePath™ vial.
BD SurePath™ Collection process
Step 3: Send

Place the cap on the vial and tighten. Send the BD SurePath™ vial to the lab for processing.
BD SurePath™ Collection process

The BD SurePath™ Process in the laboratory.

Try BD SurePath™ Pap test in your practice.

1 Kurman RJ, Solomon D (editors). The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses: Definitions, Criteria and Explanatory Notes for Terminology and Specimen Adequacy. New York, Springer Verlag, 1994.
2BD PrepStain™ Slide Processor Product Insert. Direct-to-Vial study population.
3BD PrepStain™ Slide Processor Product Insert. Split-sample study population.
4Bigras G., et al. Keeping collecting device in liquid medium is mandatory to ensure optimized liquid-based cervical cytologic sampling. Journal of Lower Genital Tract Disease, Vol. 7(3), 2003:168-174.

 

Unless otherwise noted, BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2014 BD